A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

Trial Profile

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs NY-ESO-1c259 TCR-transduced lymphocytes (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Synovial sarcoma
  • Focus Therapeutic Use
  • Sponsors Adaptimmune
  • Most Recent Events

    • 09 Nov 2017 According to an Adaptimmune media release, updated results of all cohorts of the study were presented at the annual CTOS meeting.
    • 09 Nov 2017 Results published in an Adaptimmune media release.
    • 03 Nov 2017 According to an Adaptimmune media release, data from the study will be presented at the upcoming CTOS meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top